Catalent to Mass-Produce a Coronavirus Vaccine for AstraZeneca and Oxford University
On Monday, one of the biopharmaceutical industry's largest contract manufacturers signed an agreement that could lead to the production of hundreds of millions of doses of a SARS-CoV-2 vaccine. Catalent (NYSE: CTLT) will work with AstraZeneca (NYSE: AZN) and Oxford University to develop AZD1222, an experimental vaccine to prevent people from being infected by the coronavirus that causes COVID-19.
The process of developing a new vaccine can be a long, frustrating walk with hidden pitfalls lurking at every step. As a 2013 study from the Pharmaceutical Research and Manufacturers of America noted, fewer than 10% of all vaccine candidates succeed in clinical trials well enough to be licensed for use. While more than 100 organizations and companies are currently working on dozens of SARS-CoV-2 vaccine candidates, the Trump administration has selected a handful to receive extra support -- one of which is AZD1222.
Image source: Getty Images.
Source Fool.com
